Currently pregnant or breastfeeding-Neither Page 4 Posts on Medivizor
Navigation Menu

Currently pregnant or breastfeeding-Neither Posts on Medivizor

Looking for patients with relapsed follicular, marginal zone, or mantle cell lymphoma to test the effectiveness of a rituximab and lenalidomide maintenance therapy

Posted by on Sep 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....

Read More

Looking for patients with relapsed or refractory B-cell lymphoma to test the effectiveness of radioimmunotherapy followed by chemotherapy before stem cell transplant

Posted by on Sep 11, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of yttrium-90 (Y-90)-ibritumomab tiuxetan (Zevalin) followed by fludarabine (Fludara), total body irradiation, and donor peripheral blood stem cell transplant (PBSCT) in patients with relapsed or refractory (did not respond to treatment) B-cell lymphoma. The primary...

Read More

Searching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...

Read More

Searching for patients with relapsed or refractory acute myeloid leukemia to test an immunotherapy

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 1 clinical trial will test the safety and effectiveness of AMV564 in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by adverse (negative) side effects and remission rate. The study is being conducted in Saint Louis, Missouri, New York City, and...

Read More

Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment

Posted by on Sep 3, 2017 in Leukemia | 0 comments

In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...

Read More

Looking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma

Posted by on Aug 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate.   The details Axicabtagene ciloleucel is a chimeric antigen...

Read More

Looking for patients to test the safety of CAR T-cells in treating relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Aug 21, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 clinical trial will test the safety of JCAR017 CAR T-cells in treating patients with relapsed or refractory (unresponsive to treatment) B-cell non-Hodgkin’s lymphoma. The primary outcome with be measured by adverse (negative) side effects, maximum dosage, response rate, and concentration of JCAR017.   The...

Read More

Looking for patients with relapsed or refractory follicular or diffuse large B-cell lymphoma to test a combination therapy containing polatuzumab vedotin antibody-drug conjugate

Posted by on Aug 21, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of polatuzumab vedotin with obinutuzumab (Gazyva) and venetoclax (Venclexta) in patients with relapsed or refractory follicular lymphoma (FL) or rituximab (Rituxan) with polatuzumab vedotin and venetoclax in patients with relapsed or refractory diffuse large B-cell...

Read More

Looking for patients with inflammatory breast cancer to test eribulin followed by chemotherapy

Posted by on Jul 4, 2016 in Breast cancer | 0 comments

In a nutshell The main objective of this trial is to determine patient response to eribulin (Halaven) followed by doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) treatment. The main outcome to be measured is number of patients who experience a complete response to treatment (disappearance of signs of cancer). This trial is being conducted...

Read More

Chemotherapy before surgery; is there a different in outcome between different types of breast cancer?

Posted by on May 14, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to evaluate if the outcomes of surgery following chemotherapy are different based on the focality of breast cancer tumors.  Some background Breast cancer can be characterised as 'unifocal', 'multifocal and 'multicentric'. This refers to the number of areas in which the cancer can be found...

Read More

An analysis of TNF-blocking agents in combination with methotrexate for active rheumatoid arthritis

Posted by on Apr 13, 2014 in Rheumatoid Arthritis | 0 comments

In a nutshell This analysis investigated the benefits of combined methotrexate (MTX) and tumor necrosis factor (TNF) blockers in the treatment of active rheumatoid arthritis. Some background Rheumatoid arthritis (RA) is characterized by the improper activation of the immune system leading to chronic inflammation and joint damage. Active RA is...

Read More